Dulanermin - Shanghai GeBaiDe

Drug Profile

Dulanermin - Shanghai GeBaiDe

Alternative Names: Apo2L/TRAIL - Shanghai GeBaiDe; recombinant human apoptosis-2 ligand - Shanghai Qiaer; Recombinant Human TRAIL/Apo2L - Shanghai GeBaiDe; Rh-Apo2L; TNFSF10

Latest Information Update: 11 Feb 2016

Price : $50

At a glance

  • Originator Shanghai Qiaer Bio-Technology
  • Developer Shanghai GeBaiDe Biotechnical Co
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Feb 2016 No recent reports on development identified - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Locally recurrent) in China (Parenteral)
  • 18 Sep 2009 Phase-III clinical trials in Non-small cell lung cancer (combination therapy, late-stage disease, locally-recurrent) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top